Abstract
METHODS
Between 2018 and 2022 patients scheduled to receive nCRT followed by surgery were prospectively included in 4 tertiary referral centers in The Netherlands. A 18FDG-PET-CT, DW-MRI, and DCE-MRI was performed before, during, and after nCRT. Tumor volumes were (semi-)automatically segmented and mean and max standard uptake volume (SUVmean and SUVmax) and tumor lesion glycolysis (TLG), mean and max apparent diffusion coefficient (ADC), and transfer constants Ktrans and Kep were extracted from respectively 18FDG-PET-CT, DW-MRI, and DCE-MRI scans. Absolute values and relative changes during and after nCRT were analyzed. Primary outcome was pathological complete response (pCR), defined as tumor regression grade (TRG) 1, versus non-pCR. Forward feature selection logistic regression models for pCR were developed and leave one out cross-validation (LOOCV) with bootstrapping was used to estimate performance in an 'independent' dataset.
CONCLUSION
Despite promising results observed in previous smaller single-center studies, the predictive value of the investigated quantitative imaging parameters did not translate into clinically meaningful performance in this prospective multicenter setting.
RESULTS
141 patients were included in the analyses of whom 33 had a pCR and 108 non-pCR. ΔTLGper, ΔSUVmax,post, and ΔADCmean,per were best univariable predictors for pCR (AUC: 0.68, 0.64, 0.62). Combining DW-MRI, DCE MRI and 18FDG-PET features resulted in a forward feature selection logistic regression model with an AUC of 0.65 (95%CI 0.48-0.79, using parameters ΔTLG,per and ΔTLG,post) after LOOCV for predicting pCR.
BACKGROUND
Accurate response assessment after neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer patients could facilitate a more personalized treatment, including possible organ-preserving treatment for good responders or discontinuation of nCRT of poor responders.
PURPOSE
This multicenter study evaluated predictive value of fluorodeoxyglucose positron emission tomography with computed tomography (18FDG-PET-CT), diffusion weighted (DW) and dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) to assess response to nCRT in esophageal cancer patients.